The North America Oral Antiviral Market would witness market growth of 1.7% CAGR during the forecast period (2023-2029).
There is a market opportunity for oral antiviral products due to expansion and innovation in the pharmaceutical sector. Increased product approvals for various these medicines and an increase in the number of new medication studies conducted by major manufacturers are expected to benefit market growth. In addition, the demand for efficient oral antiviral medications is also increasing due to the growing incidence of viral infections, including hepatitis and influenza, propelling the market's expansion.
Due to the accessibility of enhanced healthcare infrastructure, a surge in unmet healthcare needs, a boost in the prevalence of adult cases of the human immunodeficiency virus (HIV), and an increase in the need for these medications for the treatment of viral infection, emerging markets are predicted to drive the growth of the market. Additionally, the demand for better healthcare services is growing, the government is making sizable expenditures to upgrade the healthcare infrastructure, and the medical tourism sector is expanding rapidly in emerging nations. These factors contribute to the rapid growth of the healthcare sector in these economies.
The pharmaceutical sector in Mexico is regarded as one of the biggest in the world. Patented drugs comprise 51% of the market in Mexico's pharmaceutical industry by value, followed by generic drugs with 35% of the market and over-the-counter products for the remaining 14%. The growth of biosimilars, whose sales are anticipated to rise in the future years, is one factor driving Mexico's pharmaceutical industry. With the release of updated medication guidelines, regional R&D and biosimilar industry manufacturing has substantially improved, and numerous companies have announced the introduction of novel products and investments. As a result, the region's development of oral antiviral pharmaceuticals is anticipated to boost market expansion, along with expanding drug imports and exports and a robust pharmaceutical sector.
The US market dominated the North America Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $11,996.1 million by 2029. The Canada market is registering a CAGR of 4.1% during (2023 - 2029). Additionally, The Mexico market would showcase a CAGR of 3.1% during (2023 - 2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Oral Antiviral Market is Projected to reach USD 41.2 Billion by 2029, at a CAGR of 2.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Human Immunodeficiency Virus (HIV)
- Hepatitis
- Influenza
- Others
By Drug Class
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Oral Antiviral Market, by Indication
1.4.2 North America Oral Antiviral Market, by Drug Class
1.4.3 North America Oral Antiviral Market, by Distribution Channel
1.4.4 North America Oral Antiviral Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Oral Antiviral Market by Indication
3.1 North America Human Immunodeficiency Virus (HIV) Market by Country
3.2 North America Hepatitis Market by Country
3.3 North America Influenza Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Oral Antiviral Market by Drug Class
4.1 North America Reverse Transcriptase Inhibitors Market by Country
4.2 North America Protease Inhibitors Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Oral Antiviral Market by Distribution Channel
5.1 North America Drug Store & Retail Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
5.3 North America Online Providers Market by Country
Chapter 6. North America Oral Antiviral Market by Country
6.1 US Oral Antiviral Market
6.1.1 US Oral Antiviral Market by Indication
6.1.2 US Oral Antiviral Market by Drug Class
6.1.3 US Oral Antiviral Market by Distribution Channel
6.2 Canada Oral Antiviral Market
6.2.1 Canada Oral Antiviral Market by Indication
6.2.2 Canada Oral Antiviral Market by Drug Class
6.2.3 Canada Oral Antiviral Market by Distribution Channel
6.3 Mexico Oral Antiviral Market
6.3.1 Mexico Oral Antiviral Market by Indication
6.3.2 Mexico Oral Antiviral Market by Drug Class
6.3.3 Mexico Oral Antiviral Market by Distribution Channel
6.4 Rest of North America Oral Antiviral Market
6.4.1 Rest of North America Oral Antiviral Market by Indication
6.4.2 Rest of North America Oral Antiviral Market by Drug Class
6.4.3 Rest of North America Oral Antiviral Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 SWOT Analysis
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 Gilead Sciences, Inc.
7.5.1 Company overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.6 Viatris, Inc. (Mylan N.V.)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental Analysis
7.6.4 Research & Development Expense
7.7 AbbVie, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 GlaxoSmithKline PLC (GSK)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Teva Pharmaceutical Industries Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Amneal Pharmaceuticals, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental Analysis
7.10.4 Research & Development Expenses
TABLE 1 North America Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 2 North America Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 3 North America Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 4 North America Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 5 North America Human Immunodeficiency Virus (HIV) Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Human Immunodeficiency Virus (HIV) Market by Country, 2023 - 2029, USD Million
TABLE 7 North America Hepatitis Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Hepatitis Market by Country, 2023 - 2029, USD Million
TABLE 9 North America Influenza Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Influenza Market by Country, 2023 - 2029, USD Million
TABLE 11 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 14 North America Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 15 North America Reverse Transcriptase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Reverse Transcriptase Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 17 North America Protease Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Protease Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 19 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 22 North America Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 23 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 25 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Oral Antiviral Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Oral Antiviral Market by Country, 2023 - 2029, USD Million
TABLE 31 US Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 32 US Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 33 US Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 34 US Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 35 US Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 36 US Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 37 US Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 38 US Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 39 Canada Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 40 Canada Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 41 Canada Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 42 Canada Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 43 Canada Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 44 Canada Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 45 Canada Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 46 Canada Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 47 Mexico Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 48 Mexico Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 49 Mexico Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 50 Mexico Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 51 Mexico Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 52 Mexico Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 53 Mexico Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 54 Mexico Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 55 Rest of North America Oral Antiviral Market, 2019 - 2022, USD Million
TABLE 56 Rest of North America Oral Antiviral Market, 2023 - 2029, USD Million
TABLE 57 Rest of North America Oral Antiviral Market by Indication, 2019 - 2022, USD Million
TABLE 58 Rest of North America Oral Antiviral Market by Indication, 2023 - 2029, USD Million
TABLE 59 Rest of North America Oral Antiviral Market by Drug Class, 2019 - 2022, USD Million
TABLE 60 Rest of North America Oral Antiviral Market by Drug Class, 2023 - 2029, USD Million
TABLE 61 Rest of North America Oral Antiviral Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 62 Rest of North America Oral Antiviral Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 63 Key information –Johnson & Johnson
TABLE 64 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 65 KEY INFORMATION - Merck & Co., Inc.
TABLE 66 Key Information – Bristol Myers Squibb Company
TABLE 67 Key Information – Gilead Sciences, Inc.
TABLE 68 key information – Viatris, Inc.
TABLE 69 Key information – AbbVie, Inc.
TABLE 70 Key Information – GlaxoSmithKline PLC
TABLE 71 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 72 Key Information – Amneal Pharmaceuticals, INc.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Oral Antiviral Market Share by Indication, 2022
FIG 3 North America Oral Antiviral Market Share by Indication, 2029
FIG 4 North America Oral Antiviral Market by Indication, 2019 - 2029, USD Million
FIG 5 North America Oral Antiviral Market Share by Drug Class, 2022
FIG 6 North America Oral Antiviral Market Share by Drug Class, 2029
FIG 7 North America Oral Antiviral Market by Drug Class, 2019 - 2029, USD Million
FIG 8 North America Oral Antiviral Market Share by Distribution Channel, 2022
FIG 9 North America Oral Antiviral Market Share by Distribution Channel, 2029
FIG 10 North America Oral Antiviral Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 North America Oral Antiviral Market Share by Country, 2022
FIG 12 North America Oral Antiviral Market Share by Country, 2029
FIG 13 North America Oral Antiviral Market by Country, 2019 - 2029, USD Million
FIG 14 SWOT analysis: Johnson & Johnson